Literature DB >> 32463523

The pyruvate kinase (PK) to hexokinase enzyme activity ratio and erythrocyte PK protein level in the diagnosis and phenotype of PK deficiency.

Hanny Al-Samkari1, Kathryn Addonizio2, Bertil Glader3, D Holmes Morton4,5, Satheesh Chonat6,7, Alexis A Thompson8, Kevin H M Kuo9, Yaddanapudi Ravindranath10, Heng Wang11, Jennifer A Rothman12, Janet L Kwiatkowski13, Charles Kung14, Penelope A Kosinski14, Hasan Al-Sayegh2, Wendy B London2, Rachael F Grace2.   

Abstract

Diagnosis of pyruvate kinase deficiency (PKD), the most common cause of hereditary non-spherocytic haemolytic anaemia, remains challenging in routine practice and no biomarkers for clinical severity have been characterised. This prospective study enrolled 41 patients with molecularly confirmed PKD from nine North American centres to evaluate the diagnostic sensitivity of pyruvate kinase (PK) enzyme activity and PK:hexokinase (HK) enzyme activity ratio, and evaluate the erythrocyte PK (PK-R) protein level and erythrocyte metabolites as biomarkers for clinical severity. In this population not transfused for ≥90 days before sampling, the diagnostic sensitivity of the PK enzyme assay was 90% [95% confidence interval (CI) 77-97%], whereas the PK:HK ratio sensitivity was 98% (95% CI 87-100%). There was no correlation between PK enzyme activity and clinical severity. Transfusion requirements correlated with normalised erythrocyte ATP levels (r = 0·527, P = 0·0016) and PK-R protein levels (r = -0·527, P = 0·0028). PK-R protein levels were significantly higher in the never transfused [median (range) 40·1 (9·8-73·9)%] versus ever transfused [median (range) 7·7 (0·4-15·1)%] patients (P = 0·0014). The PK:HK ratio had excellent sensitivity for PK diagnosis, superior to PKLR exon sequencing. Given that the number of PKLR variants and genotype combinations limits prognostication based on molecular findings, PK-R protein level may be a useful prognostic biomarker of disease severity and merits further study.
© 2020 British Society for Haematology and John Wiley & Sons Ltd.

Entities:  

Keywords:  enzyme assay; hexokinase; pyruvate kinase; pyruvate kinase deficiency; pyruvate kinase protein

Mesh:

Substances:

Year:  2020        PMID: 32463523     DOI: 10.1111/bjh.16724

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  3 in total

1.  Decreased activity and stability of pyruvate kinase in sickle cell disease: a novel target for mitapivat therapy.

Authors:  Minke A E Rab; Jennifer Bos; Brigitte A van Oirschot; Stephanie van Straaten; Penelope A Kosinski; Victor Chubukov; Hyeryun Kim; Heidi Mangus; Roger E G Schutgens; Gerard Pasterkamp; Lenny Dang; Charles Kung; Eduard J van Beers; Richard van Wijk
Journal:  Blood       Date:  2021-05-27       Impact factor: 22.113

Review 2.  Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias.

Authors:  Hanny Al-Samkari; Eduard J van Beers
Journal:  Ther Adv Hematol       Date:  2021-12-21

3.  Health-related quality of life and fatigue in children and adults with pyruvate kinase deficiency.

Authors:  Hanny Al-Samkari; Eduard J van Beers; D Holmes Morton; Stefan W Eber; Satheesh Chonat; Kevin H M Kuo; Nina Kollmar; Heng Wang; Vicky R Breakey; Sujit Sheth; Mukta Sharma; Peter W Forbes; Robert J Klaassen; Rachael F Grace
Journal:  Blood Adv       Date:  2022-03-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.